$13.92 Million in Sales Expected for Minerva Surgical, Inc. (NASDAQ:UTRS) This Quarter

Analysts expect Minerva Surgical, Inc. (NASDAQ:UTRSGet Rating) to report $13.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Minerva Surgical’s earnings, with the lowest sales estimate coming in at $13.11 million and the highest estimate coming in at $14.83 million. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Minerva Surgical will report full-year sales of $61.13 million for the current fiscal year, with estimates ranging from $60.52 million to $61.83 million. For the next financial year, analysts anticipate that the firm will report sales of $80.78 million, with estimates ranging from $79.50 million to $81.82 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Minerva Surgical.

Minerva Surgical (NASDAQ:UTRSGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07).

Several research firms recently issued reports on UTRS. Zacks Investment Research downgraded Minerva Surgical from a “hold” rating to a “sell” rating in a report on Wednesday. Piper Sandler cut their price target on Minerva Surgical from $12.00 to $6.00 in a report on Thursday, May 12th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, Minerva Surgical has a consensus rating of “Buy” and an average price target of $10.50.

NASDAQ UTRS opened at $2.58 on Friday. Minerva Surgical has a fifty-two week low of $1.61 and a fifty-two week high of $10.37. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.32 and a quick ratio of 1.72. The stock’s fifty day moving average is $3.73 and its two-hundred day moving average is $5.12.

Several hedge funds have recently bought and sold shares of UTRS. Vanguard Group Inc. boosted its holdings in Minerva Surgical by 64.8% in the first quarter. Vanguard Group Inc. now owns 378,781 shares of the company’s stock valued at $1,705,000 after acquiring an additional 148,915 shares during the last quarter. Millennium Management LLC purchased a new position in Minerva Surgical in the fourth quarter valued at about $134,000. BlackRock Inc. purchased a new stake in shares of Minerva Surgical during the fourth quarter worth about $88,000. Renaissance Technologies LLC bought a new stake in Minerva Surgical in the fourth quarter valued at about $78,000. Finally, Virtu Financial LLC bought a new stake in Minerva Surgical in the fourth quarter valued at about $54,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

About Minerva Surgical (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Further Reading

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Surgical (NASDAQ:UTRS)

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.